Medytox, Inc. Announces The Formation Of Luvantas Subsidiary And Appointment Of Key Executives

Medytox, Inc. Announces The Formation Of Luvantas Subsidiary And Appointment Of Key Executives

IRVINE, Calif., Jan. 3, 2024 /PRNewswire/ -- Meditox, Inc. Luvantas is an innovative medical aesthetic company committed to bringing innovative solutions to the North American market, face to face for clients, patients and colleagues. Levantas is working with Meditox to seek approval for the upcoming launch of its nevobotulinumtoxinA in the US and Canada . A biologics license application was submitted to the US FDA in December. Further information on the structure of this advanced botulinum toxin will be provided upon receipt of regulatory approval. Luvantas intends to obtain approval from Medytox to launch other new aesthetic treatment offerings, as well as partner with new companies and innovators to bring unique aesthetic treatment solutions to market.

A key executive has been appointed

In the formation of Levantes , Thomas A. Albright as president and CEO and Stephanie A. You have been appointed CFO.

As CEO, Tom brings 40 years of healthcare experience to Luvantas, leading in medical aesthetics since 2000. Mr. Albright was previously CEO of Recross Medica in 2017 and CEO of Andrew Technologies from 2011 to 2017. He was previously president of Syneron Current Affairs. Division and Cinero. He was previously Vice President of North American Marketing at Nobel Biocare. Tom began his medical aesthetic practice in 2000 at Allergan, where he led the global launch of BOTOX ® Cosmetic. In 2008, he completed his tenure at Allergan as Vice President of Global Strategic Marketing for BOTOX ® , leading research and development for new therapeutic indications and next-generation biologics. While at Allergan, Tom led the commercial development of Latisse® and served as a functional alliance manager with GlaxoSmithKline in Japan and China . Tom began his health sciences career at Warner-Lambert Park's Davis Division in 1983, starting as a sales representative and later becoming director of marketing. Mr. Albright holds a BA in Biology from The Citadel and an MBA in Marketing from Mercer University .

As a CFO, Stephanie has more than 20 years of accounting and finance experience in high-growth science and technology companies, from startups to large global corporations. Prior to joining Luvantas, Stephanie served as Vice President of Finance at Allegro Ophthalmics LLC, a leading biopharmaceutical company, leading corporate development and financial operations. Stephanie previously worked at ZO Skin Health Inc. He served as corporate controller, expanding the accounting and finance firm to achieve broad revenue growth and ClaripHy Communications Inc. Facilitated the sale of the company to Infi. . Previously, Stephanie held several leadership positions at Emulex Corporation, where she played a key role in several merger and acquisition projects. Prior to Emulex, Ms. Yee worked for IntraLase Corporation, Advanced Medical Optics, Inc. Where did he work? He supported their international expansion and acquisitions, which are now part of Johnson & Johnson . Ms. Yeh holds a bachelor's degree in accounting from the University of British Columbia and is a certified public accountant in Illinois and British Columbia .

About Meditox, Inc

Meditox is a world-renowned biopharmaceutical company with a rich history of innovation in medical aesthetics. Founded in 2000 and based in South Korea, Meditox is a genuine Korean manufacturer of botulinum toxin type A and the first company to introduce ready-to-use liquid formulations. Meditox products are sold in 60 countries, providing a broad portfolio of dermal fillers and topical skin treatments, as well as botulinum toxin products in international markets outside the US . Meditox is listed on Korea's KOSDAQ stock exchange (086900.KQ). http://medytox.com

Media communication
Email: media@luvantas.com

Original content for multimedia download: https://www.prnewswire.com/news-releases/medytox-inc-announces-the-formation-of-luvantas-subsidiary-and-appointment-of-key-executives-302025050.html

Source: Luvantas, Inc

Post a Comment (0)
Previous Post Next Post